More Viagra-like Drugs

Join Our Community of Science Lovers!


On supporting science journalism

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.


When Viagra was introduced in 1999, it became a household word seemingly overnight. Since then, its potent effect on erectile dysfunction has made it one of the most widely prescribed drugs. Viagra, however, is only one member of a class of agents known as phosphodiesterase inhibitors, and the success of the little blue pill has raised considerable interest in the potential of its classmates to combat a variety of other conditions. Joseph Beavo of the University of Washington discussed these prospects on Saturday at the annual meeting of the American Association for the Advancement of Science in San Francisco.

Viagra inhibits a type of enzyme found in the penis called a cyclic GMP phosphodiesterase (PDE). But there are many kinds of PDEs, Beavo explains. In fact, 11 families of the enzymes are known so far. PDEs play an important role in sensory processes, including vision and smell, and they may likewise contribute to learning and memory. Research conducted in Beavo's lab has also identified PDEs that appear to mediate immune system activity. Scientists are thus investigating whether inhibiting these enzymes might help control anti-immune and hyperinflammatory diseases, such as rheumatoid arthritis and allergies. Other PDEs are involved in insulin secretion and leptin signaling, and so might be good targets in treating diabetes and obesity.

"Different PDEs are expressed in different tissues and in different parts of the cell, and have different physiological functions," Beavo explains. "The challenge has been for the drug companies to find agents that are selective for specific phosphodiesterases so that they can treat the disease without causing toxic side effects." Yet because a number of PDEs have been discovered within the past year, the search for those with Viagra-like specificity has only just begun. In the future, PDEs could even be used to enhance memory and to treat chronic obstructive pulmonary disease and blood clotting disorders. But much research and testing will be needed before any of these visions come to pass.

Kate Wong is an award-winning science writer and senior editor for features at Scientific American, where she has focused on evolution, ecology, anthropology, archaeology, paleontology and animal behavior. She is fascinated by human origins, which she has covered for nearly 30 years. Recently she has become obsessed with birds. Her reporting has taken her to caves in France and Croatia that Neandertals once called home to the shores of Kenya’s Lake Turkana in search of the oldest stone tools in the world, as well as to Madagascar on an expedition to unearth ancient mammals and dinosaurs, the icy waters of Antarctica, where humpback whales feast on krill, and a “Big Day” race around the state of Connecticut to find as many bird species as possible in 24 hours. Wong is co-author, with Donald Johanson, of Lucy’s Legacy: The Quest for Human Origins. She holds a bachelor of science degree in biological anthropology and zoology from the University of Michigan. Follow her on Bluesky @katewong.bsky.social

More by Kate Wong

It’s Time to Stand Up for Science

If you enjoyed this article, I’d like to ask for your support. Scientific American has served as an advocate for science and industry for 180 years, and right now may be the most critical moment in that two-century history.

I’ve been a Scientific American subscriber since I was 12 years old, and it helped shape the way I look at the world. SciAm always educates and delights me, and inspires a sense of awe for our vast, beautiful universe. I hope it does that for you, too.

If you subscribe to Scientific American, you help ensure that our coverage is centered on meaningful research and discovery; that we have the resources to report on the decisions that threaten labs across the U.S.; and that we support both budding and working scientists at a time when the value of science itself too often goes unrecognized.

In return, you get essential news, captivating podcasts, brilliant infographics, can't-miss newsletters, must-watch videos, challenging games, and the science world's best writing and reporting. You can even gift someone a subscription.

There has never been a more important time for us to stand up and show why science matters. I hope you’ll support us in that mission.

Thank you,

David M. Ewalt, Editor in Chief, Scientific American

Subscribe